Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial
Background Reports on controlled trials on the efficacy and tolerability of sulfonated shale oils in atopic eczema are not available so far. The aim of this study was to investigate whether topically applied, specially prepared pale sulfonated shale oil (PSSO) cream is capable of improving symptoms...
Saved in:
Published in | Journal of the European Academy of Dermatology and Venereology Vol. 24; no. 10; pp. 1176 - 1182 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.10.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background Reports on controlled trials on the efficacy and tolerability of sulfonated shale oils in atopic eczema are not available so far. The aim of this study was to investigate whether topically applied, specially prepared pale sulfonated shale oil (PSSO) cream is capable of improving symptoms/signs of mild to moderate atopic eczema in children more efficaciously than a corresponding vehicle cream.
Patients and methods A total of 99 children suffering from mild to moderate atopic eczema were enrolled in this multicentre, randomized, vehicle‐controlled study. Verum or vehicle cream was applied to the affected skin area three times a day over 4 weeks. As the primary outcome parameter served the reduction of the total score after 4 weeks of treatment, compared with the initial examination. Secondary outcome parameters were addressed as well. Tolerability was judged by investigators and patients/parents, and adverse events were documented.
Results After 4 weeks of treatment, the total score declined from 13.4 ± 3.7 to 4.5 ± 7.4 score points in the verum group and from 13.0 ± 3.1 to 11.7 ± 8.6 score points in the vehicle group (P < 0.0001). The superiority of verum regarding total score was already apparent after a treatment period of 1 week (reduction by 5.6 ± 4.3 vs. 1.3 ± 5.9 score points; P < 0.0001). Tolerability was found superior at the end of the treatment in the verum when compared with the control group – both by investigators (P < 0.0001) and patients/parents (P = 0.0051).
Conclusion Pale sulfonated shale oil cream 4% is capable to treat mild to moderate atopic eczema in children more efficaciously than vehicle and is well tolerated. PSSO thus represents a valuable addition to our therapeutic armamentarium. PSSO should be considered in particular when valid alternatives for topical glucocorticoids are sought for. |
---|---|
Bibliography: | ark:/67375/WNG-PVS53B94-W ArticleID:JDV3616 istex:274A4C5AD8F3642D61AE8903157D0957647BDC8D Further investigators Biometrician Conflict of interest Dr. B. Fassnacht and Dr. Peter Reichmann, Staufenbergzentrum, Staufenbergstr. 31, 74081 Heilbronn, Germany; Dr. Andreas Kohl, Rutkamp 1–3, 24111 Kiel, Germany. Dr. Klaus Chelius, Frankfurter Street 593, 51145 Köln, Germany. Principal investigator Dipl. Math. Peter Klein, d.s.h. Statistical Services GmbH, Bahnhofstr. 20, 85296 Rohrbach/Ilm, Germany. The preparation of this article was supported by an educational grant to Dr Schöllmann. Prof. Korting collaborates with Ichthyol‐Gesellschaft, Hamburg, in the development of topical drugs for skin diseases. Dr Cholcha and Dr Wolff are employed by the company that supported this multicentre study but do not have any personal financial interest in the research described in the manuscript. Data analysis and interpretation were not influenced by the company. Collaborative Study Group ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 |
ISSN: | 0926-9959 1468-3083 |
DOI: | 10.1111/j.1468-3083.2010.03616.x |